Bottom line
FBDIX vs SHPAX: the short answer
FBDIX (Franklin Biotechnology Discovery Fund) and SHPAX (Health & Biotechnology Portfolio) are quite different portfolios: only about 19% of their top holdings (by weight) are shared.
But FBDIX is far broader, holding 126 positions to 29 for SHPAX, so beyond the top names it adds exposure SHPAX doesn't have.
FBDIX is cheaper at 1.01% vs 3% — a difference of $199 a year per $10,000 invested.
Over five years, FBDIX returned +5.0% a year vs +3.1% for SHPAX (reporting dates differ).
Updated Nov 19, 2026
FBDIX vs SHPAX side by side
| FBDIX | SHPAX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Franklin Templeton | Saratoga Advantage |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 1.01% | 3% |
| Annual cost per $10k | $101 | $300 |
| 10-yr cost on $10k (prospectus) | $1,728 | $3,702 |
| Max front load | 5.5% | 5.75% |
| 12b-1 fee | 0.25% | — |
| 1-yr return | +43.9% | −5.5% |
| 5-yr return (annualized) | +5.0% | +3.1% |
| 10-yr return (annualized) | +6.4% | +4.1% |
| Best quarter | +29.5% | +15.0% |
| Worst quarter | −24.5% | −13.0% |
| Net assets (fund) | $1.2B | $10.5M |
| Number of holdings | 126 | 29 |
| Portfolio turnover | 38% | 22% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBDIX | SHPAX | Difference |
|---|---|---|---|
| 2024 | +4.0% | +0.3% | +3.7% |
| 2023 | +18.4% | −0.4% | +18.8% |
| 2022 | −12.7% | +2.0% | −14.7% |
| 2021 | −17.7% | +16.7% | −34.4% |
| 2020 | +29.9% | +3.6% | +26.3% |
| 2019 | +34.8% | +16.2% | +18.7% |
| 2018 | −15.7% | −5.5% | −10.3% |
| 2017 | +18.8% | +12.0% | +6.9% |
| 2016 | −17.2% | −2.0% | −15.2% |
| 2015 | +5.5% | +6.9% | −1.4% |
Source: Fund prospectus bar charts
Holdings overlap
5 of FBDIX's top 25 holdings also appear in SHPAX's top 25.
| Holding | FBDIX | SHPAX |
|---|---|---|
| Amgen, Inc. | 4.39% | 5.04% |
| Gilead Sciences, Inc. | 3.86% | 3.94% |
| Regeneron Pharmaceuticals, Inc. | 3.77% | 3.93% |
| Vertex Pharmaceuticals, Inc. | 3.54% | 3.36% |
| Eli Lilly & Co. | 1.31% | 2.11% |
Source: SEC Form N-PORT
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
SHPAX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
FAQ
What is the difference between FBDIX and SHPAX?
Which is cheaper, FBDIX or SHPAX?
Should I own both FBDIX and SHPAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.